drugset / Trial / NCT05113394
Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy
Phase 2
Withdrawn
Boston Children's Hospital
Children's Hospital Medical Center, Cincinnati · collabEmory University · collabGeorge Washington University · collabImperial College London · collabUniversity of North Carolina, Chapel Hill · collabUniversity of Southampton · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
To establish efficacy and safety of HDM sublingual Immunotherapy (HDM-SLIT) by comparing Odactra and placebo, when given sublingually for 3 years to high risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.
Timeline
- Start
- 2027-02-01
- Primary completion
- 2028-02-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acarizax | Other / unclassified | — | Other |